Important: The POPLINE website will retire on September 1, 2019. Click here to read about the transition.

Your search found 2 Results

  1. 1
    129879

    Intercountry consultative meeting on recent advances in contraceptive technology, National Institute of Health and Family Welfare (NIH and FW) New Delhi, 1-5 December 1986.

    World Health Organization [WHO]. Regional Office for South-East Asia

    [Unpublished] 1986. 60 p. (ICP MCH 011; RAS/85/P23)

    The objectives of the intercountry consultative meeting on recent advances in contraceptive technology, held in New Delhi, India in December of 1986, were to review the state-of-the-art on contraceptive methods used in the South East Asia Region (SEAR) region of the World Health Organization (WHO); to review problems with the delivery of family planning services to the countries of SEAR; to review the status of long-acting contraceptives in the SEAR countries; and to review the newer contraceptive methods; and to make recommendations for improvement of the family planning program acceptance in theses countries. Countries include Bhutan, India, Indonesia, Maldives, Nepal, Sri Lanka, and Thailand. The current status of each country is discussed, as is methods, difficulties, and research. ICMR experience in newer contraceptive technology methods is presented, as is data related to the present status of long-acting contraceptive agents. The status of injectable contraceptives in 1986 is presented in tabular form, as is data on phase III clinical trials, and field trials. Norplant-6 was the only implantable contraceptive available for use in family planning programs. The status of implantable contraceptives, 1986; the cumulative rate per 100 Norplant acceptors per year; and the 1-year cumulative rate per 100 acceptors are given in tabular form. The WHO Special Program for Research Training and Development (HRP) has established a Task Force which is looking into the development of a contraceptive vaccine. Substances being examined include sperm antigens, oral antigens, and peptide hormones. Some antiestrogens have been promising in experimental animals as far as postovulatory contraceptives are concerned. They have not, however, been shown to be effective in humans. Recent developments in male contraception are discussed, as are problems relating to family planning programs, (FPPS). Discussions were held on newer developments and improvements related to contraceptive methods; and problems relating to family planning programs and acceptance of FPPs. Recommendations are given on both of these discussion groups.
    Add to my documents.
  2. 2
    021048

    Twelfth Annual Report.

    World Health Organization [WHO]. Special Programme of Research, Development and Research Training in Human Reproduction

    Geneva, Switzerland, WHO, 1983 Nov. 167 p.

    As the main instrument within WHO for promoting and coordinating international research and development relating to family planning, the Special Programme aims to improve the health status of the populations of developing countries by: devising improved approaches to the delivery of family planning care in the primary health care context; assessing the safety of existing methods of fertility regulation; developing new birth control technology; and generating the knowledge and technology required for the prevention and treatment of infertility. The 2nd and related objective of the Programme is to promote national self-reliance for research in family planning by collaborating with national authorities in building up manpower and facilities that will enable developing countries to plan and carry out research, adapt technology, and contribute fully to the advancement and application of science. The major topics under review are research and development, institution strengthening, dissemination of information, and relations with industry and patents. The chapter on research and development includes a discussion of: delivery of family planning care; current methods of fertility regulation; development of new methods such as new intrauterine devices, sterilization and birth control vaccines; infertility; and interagency coordination on biomedical research in fertility regulation.
    Add to my documents.